Federal Register / Vol. 80, No. 74 / Friday, April 17, 2015 / Rules and Regulations 21169 

aspiration or bone marrow biopsy, but not 

peripheral blood smears alone. Examples of 

these disorders are myelodysplastic 

syndromes, aplastic anemia, 

granulocytopenia, and myelofibrosis. 

Acquired disorders of bone marrow failure 

may result from viral infections, chemical 

exposure, or immunologic disorders. 

2. The hospitalizations in 107.10A do not 

all have to be for the same complication of 

bone marrow failure. They may be for three 

different complications of the disorder. 

Examples of complications that may result in 

hospitalization include uncontrolled 

bleeding, anemia, and systemic bacterial, 

viral, or fungal infections. 

3. For 107.10B, the requirement of life-long 

RBC transfusions to maintain life in 

myelodysplastic syndromes or aplastic 

anemias has the same meaning as it does for 

beta thalassemia major. (See 107.00C4.) 

F. How do we evaluate bone marrow or stem 

cell transplantation under 107.17? 

We will consider you to be disabled for 12 

months from the date of bone marrow or stem 

cell transplantation, or we may consider you 

to be disabled for a longer period if you are 

experiencing any serious post-transplantation 

complications, such as graft-versus-host 

(GVH) disease, frequent infections after 

immunosuppressive therapy, or significant 

deterioration of organ systems. We do not 

restrict our determination of the onset of 

disability to the date of the transplantation in 

107.17. We may establish an earlier onset of 

disability due to your transplantation if 

evidence in your case record supports such 

a finding. 

G. How do we consider your symptoms, 

including your pain, severe fatigue, and 

malaise? 

Your symptoms, including pain, severe 

fatigue, and malaise, may be important 

factors in our determination whether your 

hematological disorder meets or medically 

equals a listing, or in our determination 

whether you otherwise have marked and 

severe functional limitations. We cannot 

consider your symptoms unless you have 

medical signs or laboratory findings showing 

the existence of a medically determinable 

impairment(s) that could reasonably be 

expected to produce the symptoms. If you 

have such an impairment(s), we will evaluate 

the intensity, persistence, and functional 

effects of your symptoms using the rules 

throughout 107.00 and in our other 

regulations. (See sections 416.928 and 

416.929 of this chapter.) Additionally, when 

we assess the credibility of your complaints 

about your symptoms and their functional 

effects, we will not draw any inferences from 

the fact that you do not receive treatment or 

that you are not following treatment without 

considering all of the relevant evidence in 

your case record, including any explanations 

you provide on why you are not receiving or 

following treatment. 

H. How do we evaluate episodic events in 

hematological disorders? 

Some of the listings in this body system 

require a specific number of events within a 

consecutive 12-month period. (See 107.05, 

107.08, and 107.10A.) When we use such 

criteria, a consecutive 12-month period 

means a period of 12 consecutive months, all 

or part of which must occur within the 

period we are considering in connection with 

your application or continuing disability 

review. These events must occur at least 30 

days apart to ensure that we are evaluating 

separate events. 

I. How do we evaluate hematological 

disorders that do not meet one of these 

listings? 

1. These listings are only common 

examples of hematological disorders that we 

consider severe enough to result in marked 

and severe functional limitations. If your 

disorder does not meet the criteria of any of 

these listings, we must consider whether you 

have a disorder that satisfies the criteria of 

a listing in another body system. For 

example, we will evaluate hemophilic joint 

deformity under 101.00; polycythemia vera 

under 103.00, 104.00, or 111.00; chronic iron 

overload resulting from repeated RBC 

transfusion (transfusion hemosiderosis) 

under 103.00, 104.00, or 105.00; and the 

effects of intracranial bleeding or stroke 

under 111.00 or 112.00. 

2. If you have a severe medically 

determinable impairment(s) that does not 

meet a listing, we will determine whether 

your impairment(s) medically equals a 

listing. (See section 416.926 of this chapter.) 

Hematological disorders may be associated 

with disorders in other body systems, and we 

consider the combined effects of multiple 

impairments when we determine whether 

they medically equal a listing. If your 

impairment(s) does not medically equal a 

listing, we will also consider whether it 

functionally equals the listings. (See section 

416.926a of this chapter.) We use the rules 

in § 416.994a of this chapter when we decide 

whether you continue to be disabled. 

107.01 Category of Impairments, 

Hematological Disorders 

107.05 Hemolytic anemias, including 

sickle cell disease, thalassemia, and their 

variants (see 107.00C), with: 

A. Documented painful (vaso-occlusive) 

crises requiring parenteral (intravenous or 

intramuscular) narcotic medication, 

occurring at least six times within a 12- 

month period with at least 30 days between 

crises. 

OR 

B. Complications of hemolytic anemia 

requiring at least three hospitalizations 

within a 12-month period and occurring at 

least 30 days apart. Each hospitalization must 

last at least 48 hours, which can include 

hours in a hospital emergency department or 

comprehensive sickle cell disease center 

immediately before the hospitalization (see 

107.00C2). 

OR 

C. Hemoglobin measurements of 7.0 grams 

per deciliter (g/dL) or less, occurring at least 

three times within a 12-month period with at 

least 30 days between measurements. 

OR 

D. Beta thalassemia major requiring lifelong RBC transfusions at least once every 6 

weeks to maintain life (see 107.00C4). 

107.08 Disorders of thrombosis and 

hemostasis, including hemophilia and 

thrombocytopenia (see 107.00D), with 

complications requiring at least three 

hospitalizations within a 12-month period 

and occurring at least 30 days apart. Each 

hospitalization must last at least 48 hours, 

which can include hours in a hospital 

emergency department or comprehensive 

hemophilia treatment center immediately 

before the hospitalization (see 107.00D2). 

107.10 Disorders of bone marrow failure, 

including myelodysplastic syndromes, 

aplastic anemia, granulocytopenia, and 

myelofibrosis (see 107.00E), with: 

A. Complications of bone marrow failure 

requiring at least three hospitalizations 

within a 12-month period and occurring at 

least 30 days apart. Each hospitalization must 

last at least 48 hours, which can include 

hours in a hospital emergency department 

immediately before the hospitalization (see 

107.00E2). 

OR 

B. Myelodysplastic syndromes or aplastic 

anemias requiring life-long RBC transfusions 

at least once every 6 weeks to maintain life 

(see 107.00E3). 

107.17 Hematological disorders treated by 

bone marrow or stem cell transplantation 

(see 107.00F). Consider under a disability for 

at least 12 consecutive months from the date 

of transplantation. After that, evaluate any 

residual impairment(s) under the criteria for 

the affected body system. 

* * * * * 

[FR Doc. 2015–08849 Filed 4–16–15; 8:45 am] 

BILLING CODE 4191–02–P 

DEPARTMENT OF THE TREASURY 

Internal Revenue Service 

26 CFR Part 1 

[TD 9674] 

RIN 1545–BM07 

Guidelines for the Streamlined Process 

of Applying for Recognition of Section 

501(c)(3) Status; Correction 

AGENCY: Internal Revenue Service (IRS), 

Treasury. 

ACTION: Final rule; correction. 

SUMMARY: This document contains a 

correction to final and temporary 

regulations (TD 9674) that were 

published in the Federal Register on 

Wednesday, July 2, 2014 (79 FR 37630). 

The final and temporary regulations 

provide guidance to eligible 

organizations seeking recognition of taxexempt status under section 501(c)(3) of 

the Internal Revenue Code. 

DATES: This correction is effective April 

17, 2015 and applicable July 2, 2014. 

FOR FURTHER INFORMATION CONTACT: 

James R. Martin and Robin Ehrenberg, at 

(202) 317–5800 (not a toll free number). 

SUPPLEMENTARY INFORMATION: 


asabaliauskas on DSK5VPTVN1PROD with RULES
21170 Federal Register / Vol. 80, No. 74 / Friday, April 17, 2015 / Rules and Regulations 

Background 

The final and temporary regulations 

(TD 9674) that are the subject of this 

correction are under section 501(c)(3) of 

the Internal Revenue Code. 

Need for Correction 

As published, the final and temporary 

regulation (TD 9674) contains an error 

and is in need of clarification. 

Correction of Publication 

In FR Doc. 2014–15623 appearing on 

page 37630 in the Federal Register of 

Wednesday, July 2, 2014, the following 

correction is made: 

§ 1.508–1T [Corrected] 

On page 37632, the amendatory 

instruction reading ‘‘Par. 7. Section 

1.508–1T is revised to read as follows: 

’’ is corrected to read ‘‘Par. 7. Section 

1.508–1T is added to read as follows:’’. 

Martin V. Franks, 

Chief, Publications and Regulations Branch, 

Legal Processing Division, Associate Chief 

Counsel (Procedure and Administration). 

[FR Doc. 2015–08856 Filed 4–16–15; 8:45 am] 

BILLING CODE 4830–01–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

40 CFR Part 52 

[EPA–R04–OAR–2014–0867; FRL–9926–41– 

Region–4] 

Approval and Promulgation of 

Implementation Plans; Alabama: NonInterference Demonstration for Federal 

Low-Reid Vapor Pressure Requirement 

for the Birmingham Area 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Final rule. 

SUMMARY: The Environmental Protection 

Agency (EPA) is approving the State of 

Alabama’s November 14, 2014, State 

Implementation Plan (SIP) revision, 

submitted through the Alabama 

Department of Environmental 

Management (ADEM), in support of the 

State’s request that EPA change the 

Federal Reid Vapor Pressure (RVP) 

requirements for Jefferson and Shelby 

Counties (hereinafter referred to as the 

‘‘Birmingham Area’’ or ‘‘Area’’). 

Alabama’s November 14, 2014, SIP 

revision evaluates whether changing the 

Federal RVP requirements in this Area 

would interfere with the Area’s ability 

to meet the requirements of the Clean 

Air Act (CAA or Act). Specifically, 

Alabama’s SIP revision concludes that 

relaxing the Federal RVP requirement 

from 7.8 pounds per square inch (psi) to 

9.0 psi for gasoline sold between June 1 

and September 15 of each year in the 

Area would not interfere with 

attainment or maintenance of the 

national ambient air quality standards 

(NAAQS) or with any other CAA 

requirement. EPA has determined that 

Alabama’s November 14, 2014, SIP 

revision is consistent with the CAA. 

DATES: This rule will be effective April 

17, 2015. 

ADDRESSES: EPA has established a 

docket for this action under Docket 

Identification No. EPA–R04–OAR– 

2014–0867. All documents in the docket 

are listed on the www.regulations.gov 

Web site. Although listed in the index, 

some information is not publicly 

available, i.e., Confidential Business 

Information or other information whose 

disclosure is restricted by statute. 

Certain other material, such as 

copyrighted material, is not placed on 

the Internet and will be publicly 

available only in hard copy form. 

Publicly available docket materials are 

available either electronically through 

www.regulations.gov or in hard copy at 

the Air Regulatory Management Section 

(formerly the Regulatory Development 

Section), Air Planning and 

Implementation Branch (formerly the 

Air Planning Branch), Air, Pesticides 

and Toxics Management Division, U.S. 

Environmental Protection Agency, 

Region 4, 61 Forsyth Street SW., 

Atlanta, Georgia 30303–8960. EPA 

requests that if at all possible, you 

contact the person listed in the FOR

FURTHER INFORMATION CONTACT section to 

schedule your inspection. The Regional 

Office’s official hours of business are 

Monday through Friday, 8:30 a.m. to 

4:30 p.m., excluding Federal holidays. 

FOR FURTHER INFORMATION CONTACT: 

Richard Wong of the Air Regulatory 

Management Section, in the Air 

Planning and Implementation Branch, 

Air, Pesticides and Toxics Management 

Division, U.S. Environmental Protection 

Agency, Region 4, 61 Forsyth Street 

SW., Atlanta, Georgia 30303–8960. Mr. 

Wong may be reached by phone at (404) 

562–8726 or via electronic mail at 

wong.richard@epa.gov. 

SUPPLEMENTARY INFORMATION: 

I. What is the background for this final 

action? 

The Birmingham Area was originally 

designated as a 1-hour ozone 

nonattainment area by EPA on March 3, 

1978 (43 FR 8962). A 7.8 psi Federal 

RVP requirement was first applied to 

the Area during the high ozone season 

given its status as a marginal 

nonattainment area for the 1-hour ozone 

standard. Subsequently, in order to 

comply with the 1-hour ozone NAAQS, 

Alabama opted to implement a state 

RVP requirement of 7.0 psi for gasoline 

sold in the Birmingham Area during the 

high ozone season. EPA incorporated 

the state RVP requirement of 7.0 psi for 

gasoline sold in the Birmingham Area 

into the Alabama SIP on November 7, 

2001. See 66 FR 56218. The Area 

attained the 1-hour ozone NAAQS and 

was redesignated to attainment for the 

1-hour ozone on March 12, 2004, based 

on 2001–2003 ambient air quality 

monitoring data. See 69 FR 11798. 

Alabama’s 1-hour ozone redesignation 

request did not include a request to 

remove the 7.0 psi state RVP 

requirement for the Birmingham Area 

from the SIP nor a request to relax the 

7.8 psi Federal RVP standard. 

On April 30, 2004, EPA designated 

and classified areas for the 8-hour ozone 

NAAQS that was promulgated on July 

18, 1997, as unclassifiable/attainment or 

nonattainment for the new 8-hour ozone 

NAAQS. See 69 FR 23857. The 

Birmingham Area was designated as 

nonattainment for the 1997 8-hour 

ozone NAAQS with a design value of 

0.087 parts per million (ppm). The Area 

was redesignated to attainment for the 

1997 8-hour ozone NAAQS in a final 

rulemaking on May 12, 2006. See 71 FR 

27631. Alabama’s 1997 8-hour ozone 

redesignation request did not include a 

request for the removal of the 7.8 psi 

Federal RVP standard, nor did it include 

a request to change the 7.0 psi state RVP 

requirement for the Birmingham Area. 

However, to support its request for 

redesignation to attainment for the 1997 

8-hour ozone NAAQS, Alabama took a 

conservative approach and estimated 

emissions using a 9.0 psi RVP in its 

modeling supporting the State’s 

maintenance demonstration. 

On March 2, 2012, Alabama 

submitted a SIP revision requesting that 

EPA remove the State’s 7.0 psi RVP 

requirement for the Area from the SIP. 

EPA approved Alabama’s March 2, 

2012, SIP revision on April 20, 2012. 

See 77 FR 23619. In EPA’s final 

rulemaking to remove the State RVP 

requirement, EPA noted that the action 

did not remove the 7.8 psi Federal RVP 

requirement for the Birmingham Area. 

Effective July 20, 2012, EPA designated 

the Birmingham Area as unclassifiable/ 

attainment for the 2008 8-hour ozone 

NAAQS. See 77 FR 30088 (April 30, 

2012). Although the Birmingham Area is 

designated as attainment, the federal 7.8 

psi RVP requirement remains in place. 

Alabama is now requesting that EPA 

remove the federal 7.8 psi RVP 

requirement for the Birmingham Area, 

and it submitted a SIP revision on 


asabaliauskas on DSK5VPTVN1PROD with RULES